However, ablation of APRIL with selective monoclonal antibody resulted in delayed SLE development in NZM mice and APRIL disruption in Nba2.Yaa mice improved SLE disease with reduced pathogenic antibody production and glomerulonephritis development21,22. This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.